Remegen Co., Ltd.
Clinical trials sponsored by Remegen Co., Ltd., explained in plain language.
A Chinese biopharmaceutical company developing antibody-drug conjugates and other targeted therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug trial aims to ease droopy eyelids and double vision Results expected Dec 2026 (estimated) 🚀 Make-or-break
- New drug combo aims to improve First-Line colorectal cancer treatment Results expected May 2027 (estimated)
-
New antibody RC148 takes aim at lung cancer in Head-to-Head phase 3 trial
Disease control Not yet recruitingResearchers are testing whether adding the experimental drug RC148 to platinum-based chemotherapy helps people with advanced non-squamous non-small cell lung cancer live longer without their disease worsening, compared with tislelizumab plus the same chemotherapy. The trial enrol…
Phase 3 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Sep 21, 2026 23:00 UTC
-
New drug RC288 targets Hard-to-Treat tumors in early trial
Disease control Not yet recruitingThis study tests a new drug called RC288 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check safety, find the best dose, and see if it shrinks tumors. About 326 adults aged 18 to 75 with good overall health will take …
Phase 1/2 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug aims to protect lungs in autoimmune patients
Disease control Not yet recruitingThis Phase 3 trial tests whether the drug telitacicept can slow the decline in lung function in people with connective tissue disease-related interstitial lung disease (CTD-ILD). About 260 adults with conditions like rheumatoid arthritis or lupus and confirmed lung scarring will …
Phase 3 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC